Login
Products
Login
Home
Alerts
Search
Watchlist
Products

JHS Svendgaard Laboratories Ltd

JHS
NSE
9.00
1.75%
Last Updated:
29 Apr '26, 4:00 PM
Company Overview
Alert
Watchlist
Note

JHS Svendgaard Laboratories Ltd

JHS
NSE
9.00
1.75%
29 Apr '26, 4:00 PM
Company Overview
Add Alert
Add to Watchlist
Edit Note
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
79Cr
Close
Close Price
9.00
Industry
Industry
Personal Care
PE
Price To Earnings
PS
Price To Sales
0.84
Revenue
Revenue
94Cr
Rev Gr TTM
Revenue Growth TTM
6.43%
PAT Gr TTM
PAT Growth TTM
-60.78%
Peer Comparison
How does JHS stack up?
Compare up to 10 companies side by side across valuation, profitability, and growth.
JHS
VS

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Revenue
RevenueCr
221619142224202325232223
Growth YoY
Revenue Growth YoY%
13.7-25.4-10.1-35.6-0.354.04.058.516.2-4.213.22.7
Expenses
ExpensesCr
251819142123212231222122
Operating Profit
Operating ProfitCr
-4-20012-10-5212
OPM
OPM%
-16.4-13.42.2-0.33.88.0-4.31.1-21.47.14.17.2
Other Income
Other IncomeCr
-120021010-1111
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
212222222222
PBT
PBTCr
-17-3-1100-2-2-9100
Tax
TaxCr
-6-1011180-200-1
PAT
PATCr
-11-3-10-1-1-10-2-7101
Growth YoY
PAT Growth YoY%
-141.837.720.6100.493.075.7-1,313.7-18,500.0-828.0268.398.1142.9
NPM
NPM%
-49.3-16.3-3.90.1-3.5-2.6-52.4-8.1-27.64.5-0.93.4
EPS
EPS
-1.4-0.3-0.10.0-0.1-0.1-1.2-0.2-0.80.10.00.1

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue
RevenueCr
551001051401241391018685719294
Growth
Revenue Growth%
56.880.95.033.5-11.612.2-27.6-14.4-1.7-16.529.92.4
Expenses
ExpensesCr
599493127125137998794729695
Operating Profit
Operating ProfitCr
-461214-122-1-9-1-4-1
OPM
OPM%
-7.06.411.19.8-0.51.21.9-1.0-10.7-1.3-4.4-1.2
Other Income
Other IncomeCr
-6-40327389-7401
Interest Expense
Interest ExpenseCr
001112111011
Depreciation
DepreciationCr
12106779776688
PBT
PBTCr
-22-22538-2-610-23-3-13-8
Tax
TaxCr
00-17120-104-517-3
PAT
PATCr
-22-222226-2-51-4-18-4-20-5
Growth
PAT Growth%
23.02.4201.418.8-106.4-191.2127.7-419.5-308.476.8-386.673.1
NPM
NPM%
-40.1-21.620.918.6-1.3-3.51.3-5.0-20.6-5.7-21.5-5.6
EPS
EPS
-9.1-8.35.44.5-0.1-0.30.2-0.6-2.3-0.5-2.4-0.7

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
Equity CapitalCr
243844616161646578788686
Reserves
ReservesCr
96578611311611712412195918588
Current Liabilities
Current LiabilitiesCr
491820323948231937232525
Non Current Liabilities
Non Current LiabilitiesCr
1212287818449
Total Liabilities
Total LiabilitiesCr
170121155208221241228222228197201207
Current Assets
Current AssetsCr
4336431031021301217985445459
Non Current Assets
Non Current AssetsCr
12785113105120111107143143153147148
Total Assets
Total AssetsCr
170121155208221241228222228197201207

Cash Flow

Consolidated
Standalone
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating Cash Flow
Operating Cash FlowCr
7-4-414-111012-923-9-5
Investing Cash Flow
Investing Cash FlowCr
11-3-27-7-11-2-510-21-20
Financing Cash Flow
Financing Cash FlowCr
-104101413010-2-1223
Net Cash Flow
Net Cash FlowCr
-1230-5020-1632-28-2
Free Cash Flow
Free Cash FlowCr
9-7-173-2604-169-41-15
CFO To PAT
CFO To PAT%
-32.917.4-17.953.0647.1-213.2896.1213.0-132.9226.226.2
CFO To EBITDA
CFO To EBITDA%
-187.7-58.6-33.6100.41,833.6619.0627.01,086.2-256.7979.2129.1

Ratios

Consolidated
Standalone
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
18851733271684612813310212896
Price To Earnings
Price To Earnings
-0.8-3.97.912.50.00.0105.00.030.20.00.0
Price To Sales
Price To Sales
0.30.81.62.31.40.31.31.61.21.81.0
Price To Book
Price To Book
0.10.91.31.90.90.30.70.70.70.80.6
EV To EBITDA
EV To EBITDA
-9.312.914.323.4-293.731.659.6-158.2-7.3-131.5-20.6
Profitability Ratios
Profitability Ratios
GPM
GPM%
27.026.936.335.829.928.432.229.928.837.633.6
OPM
OPM%
-7.06.411.19.8-0.51.21.9-1.0-10.7-1.3-4.4
NPM
NPM%
-40.1-21.620.918.6-1.3-3.51.3-5.0-20.6-5.7-21.5
ROCE
ROCE%
-15.9-22.14.422.3-0.6-2.11.10.8-12.7-1.7-6.8
ROE
ROE%
-18.5-22.916.914.9-0.9-2.70.7-2.3-10.1-2.4-11.6
ROA
ROA%
-13.1-17.914.112.5-0.8-2.00.6-1.9-7.7-2.1-9.8
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
### **Overview** JHS Svendgaard Laboratories Ltd. is India’s largest integrated oral care manufacturer and a leading private label and contract manufacturing partner for domestic and global FMCG brands. Established in 1996 (originally as Sunehari Svendgaard Laboratories) and incorporated in 2004, the company has evolved into a fully integrated, end-to-end FMCG manufacturing powerhouse. Listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) since 2006, JHS operates from a 20-acre, state-of-the-art manufacturing campus in Kala-Amb, Himachal Pradesh. Under the leadership of Managing Director Nikhil Nanda, the company has transitioned from a toothbrush specialist to a diversified contract manufacturer across oral care, personal care, hygiene, and emerging FMCG categories. --- ### **Core Business Segments & Manufacturing Capabilities** 1. **Oral Care (Flagship Segment)** - Products: Toothbrushes, toothpastes, mouthwashes, whitening gels, denture tablets. - **Unique Integration**: JHS is the **only company globally** that manufactures both toothbrushes (mechanical process) and toothpastes (chemical process) on a single campus, enabling **10–20% cost savings** on combo packs and private label bundles. - Capacity: Currently operating at ~70% utilization (up from ~25–30% in 2022) with significant room for scalable expansion. 2. **Personal & Home Care Diversification** - Products: Talcum powders, hand sanitizers, laundry detergents, room fresheners, hair oils, lotions, shampoos, and soaps. - **Talcum Powder**: Launched in 2023 with commercial tie-ups including Zydus Cadila’s **Nycil**, Amway, and Persona. Capacity **tripled in FY 2024–25**. - **New Plant in Jammu & Kashmir**: A ₹30 crore greenfield project expected to generate up to ₹500 crore in annual revenue and boost EBITDA margins to over 20%. 3. **Proprietary Brand – Aquawhite™** - Focus: Children’s oral care with licensed character tie-ups (e.g., **Peppa Pig, Pokémon, Chhota Bheem, Hello Kitty, SpongeBob SquarePants**). - USP: Compliance-focused, fluoride-free formulations and “Brush-Mates” engagement concept. - Marketing: “Two Two ka Formula” campaign to promote brushing habits. Among **top 3 kids’ oral care brands in Delhi-NCR** region. --- ### **Clients & Business Models** - **Contract Manufacturing (B2B Focus):** - Serves **30+ major FMCG clients** including: - **Domestic**: Dabur, HUL (Close Up, Wheel), Patanjali, Reliance Retail, Apollo Pharmacy. - **Global**: Amway, Boots, Walmart, Dr. Fresh, Gillette (Oral-B), Artsana Group (Chicco). - Exclusively manufactures **Chicco-branded toothpaste and toothbrushes** for Artsana Group in India. - Also produces for **e-commerce platforms** and **retail chains**. - **Private Label Manufacturing:** - Offers formulation development, packaging, and full production services under client brands. - **Retail (via Subsidiary):** - **JHS Svendgaard Retail Ventures Ltd.** operates airport, mall, and standalone retail stores. - Turnover: ₹1,304.81 crores in FY24, ₹1,139.22 crores in FY23. --- ### **Strategic Growth Initiatives (FY 2025–2026)** 1. **Expansion & Investment** - New **Jammu & Kashmir manufacturing facility** to enhance supply chain resilience and reduce costs. - Exploring **southern India plant** for decentralized manufacturing proximity to GST-driven local sourcing demands. - Expansion into **nutraceuticals, fast snacks, and cosmetics** under new FMCG diversification strategy. 2. **R&D & Innovation** - In-house R&D center with capabilities in Ayurvedic and chemical formulations. - Developed approved products for a **major US brand**, with plans to launch in export markets. - 6-month stability testing creates a **barrier to entry** for competitors. 3. **Global Footprint & Exports** - **Exports <1% of sales**, but strategically expanding: - Partnered with **Orazen INC (New Jersey, USA)** to launch **PEPSODENT Triple Acon** toothbrushes. - Secured export orders in **Dubai** via **Classico Brands (Inglish Popular Flexi)**. - Participated in **COSMOPROF 2024, CMPL Expo Mumbai, CPHI Noida, Private Label Middle East Dubai**. - Pursuing **FDA, ISO, GMP, SMETA certifications** for deeper global access. 4. **Merger & Synergy Strategy (Post-Vedic Merger Review)** - While proposed merger with **Vedic Cosmeceuticals** did not materialize, the strategy of **cross-selling** between oral care and personal care remains key. - Synergies expected with **existing clients** like Dabur to expand into skincare and hygiene categories. --- ### **Operational Excellence** - **Manufacturing Infrastructure**: - 6 production units: 3 for toothbrushes, 2 for toothpaste (Ayurvedic & cosmetic), 1 for talc. - **7 high-speed filling lines** (120–150 TPM). - Fully automated bristling lines (Belgium/Germany equipment). - **Quality & Certifications**: - ISO 9001, GMP, FDA, SMETA compliant. - In-house QC lab with global testing standards. - **Logistics Advantage**: - Kala-Amb campus within **1 hour** of rail, air, road, and dry port hubs. - 250,000 cubic feet warehouse capacity. --- ### **Financial & Market Highlights** - **Revenue Growth**: - 30% annual growth from FY23 to FY24 (**exceeding ₹92 crores**). - Q2 FY2024 revenue: ₹18.93 crores (19% QoQ growth). - **Profitability**: - Strategic shift to high-margin clients improved **EBITDA margins by ~1500 bps** (from negative in FY21 to double-digit). - Targeting **>20% EBITDA margin** post-Jammu expansion. - **Balance Sheet**: - **Nearly debt-free** (net debt-to-equity: 0.02 in FY22), with only minor vehicle loans. - Strong cash flow for CAPEX and expansion.